Paul E. Emery
University of Leeds · 1,687 works · 131,636 citations · h-index 163
Top works
- 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
- Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
- Treating rheumatoid arthritis to target: recommendations of an international task force
- Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
- Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
- \nEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.
- Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
- A simplified disease activity index for rheumatoid arthritis for use in clinical practice
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
- New therapies for treatment of rheumatoid arthritis
- Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci